Know Cancer

or
forgot password

A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes


Phase 3
18 Years
70 Years
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes

Inclusion Criteria


Inclusion Criteria :

- Histologically proven breast cancer. Interval between definitive surgery that
includes axillary lymph node dissection and registration is less than or equal to 60
days. A central pathology review may be performed post randomization for confirmation
of diagnosis and molecular studies.

- Definitive surgical treatment must be either mastectomy, or breast conserving surgery
with axillary lymph node dissection for operable breast cancer (T1-3, Clinical N0-1,
M0). Margins of resected specimen from definitive surgery must be histologically free
of invasive adenocarcinoma and Ductal Carcinoma In Situ (DCIS). Lobular carcinoma
in-situ does not count as a positive margin.

- Histologic examination of the tumor: Invasive adenocarcinoma with at least one
axillary lymph node (pN1) showing evidence of tumor among a minimum of six resected
lymph nodes.

- Tumor must show negative HER2 neu proto-oncogene overexpression by FISH (Fluorescence
In Situ Hybridization). Confirmation of non overexpression will be centrally assessed
by authorized BCIRG (Breast Cancer International Research Group) laboratories prior
to randomization.

- Estrogen and/or progesterone receptor analysis performed on the primary tumor prior
to randomization. Results must be known at the time of randomization.(Note: Patients
whose tumor is estrogen receptor negative with progesterone receptor status unknown
or undetermined, must have the progesterone receptor assayed in order to determine
hormonal receptor status. Patients whose tumor is progesterone receptor negative with
estrogen receptor status unknown or undetermined, must have the estrogen receptor
assayed in order to determine hormonal receptor status).

- Karnofsky Performance status index > 80%.

- Normal cardiac function must be confirmed by LVEF (Lef Ventricular Ejection Fraction)
i.e. MUGA (Multi Gated Acquisition) scan or echocardiography and ECG within 3 months
prior to registration. LVEF result must be above or equal to the lower limit of
normal for the institution. The ECG results must be within normal limits or show no
significant abnormalities.

- Laboratory requirements: (within 14 days prior to registration)

- Hematology:

- Neutrophils > or = 2.0 x 10^9/L

- Platelets > or = 100 x 10^9/L

- Hemoglobin > or = 10 g/dL

- Hepatic function:

- Total bilirubin < or = 1 UNL (Upper Normal Limit)

- ASAT (Aspartate Amino Transferase) and ALAT (Alanine Amino Transferase) <
or = 2.5 UNL

- Alkaline phosphatase < or = 5 UNL

- Patients with ASAT and/or ALAT > 1.5 x UNL associated with alkaline
phosphatase > 2.5 x UNL are not eligible for the study.

- Renal function:

- Creatinine < or = 175 ┬Ámol/L (2 mg/dL);

- If limit reached, the calculated creatinine clearance should be > or =
60mL/min.

- Complete staging work-up within 3 months prior to registration. All patients will
have contralateral mammography, chest X-ray (Posteroanterior and lateral) and/or CT
scan and/or MRI (Magnetic Resonance Imaging), abdominal ultrasound and/or CT scan
(computerized tomography) and/or MRI, and bone scan. In case of positive bone scan,
bone X-ray is mandatory to rule out the possibility of non-metastatic hot spots.
Other tests may be performed as clinically indicated.

- Negative pregnancy test (urine or serum) within 7 days prior to registration for all
women of childbearing potential.

Exclusion Criteria :

- Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy,
genetherapy , chemotherapy).

- Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.

- Prior radiation therapy for breast cancer.

- Bilateral invasive breast cancer.

- Pregnant, or lactating patients. Patients of childbearing potential must implement
adequate non-hormonal contraceptive measures during study treatment (chemotherapy and
tamoxifen therapy) and must have negative urine or serum pregnancy test within 7 days
prior to registration.

- Any T4 or N2 or known N3 or M1 breast cancer.

- Pre-existing motor or sensory neurotoxicity of a severity > grade 2 by NCI-CTC
(National Cancer Institute - Common Toxicity Criteria), version 2.0.

- Other serious illness or medical condition:

- congestive heart failure or unstable angina pectoris, previous history of
myocardial infarction within 1 year from study entry, uncontrolled hypertension
or high-risk uncontrolled arrhythmias

- history of significant neurologic or psychiatric disorders including psychotic
disorders, dementia or seizures that would prohibit the understanding and giving
of informed consent

- active uncontrolled infection

- active peptic ulcer, unstable diabetes mellitus

- Past or current history of neoplasm other than breast carcinoma, except for:

- curatively treated non-melanoma skin cancer

- carcinoma in situ of the cervix

- other cancer curatively treated and with no evidence of disease for at least 10
years

- ipsilateral ductal carcinoma in-situ (DCIS) of the breast

- lobular carcinoma in-situ (LCIS) of the breast

- Chronic treatment with corticosteroids unless initiated > 6 months prior to study
entry and at low dose (< 20 mg methylprednisolone or equivalent).

- Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment
should be stopped before study entry.

- Definite contraindications for the use of corticosteroids.

- Concurrent treatment with other experimental drugs. Participation in another clinical
trial with any investigational not marketed drug within 30 days prior to study entry.

- Concurrent treatment with any other anti-cancer therapy.

- Current therapy with any hormonal agent such as raloxifene, tamoxifen or other
selective estrogen receptor modulators (SERMs), either for osteoporosis or
prevention. Patients must have discontinued these agents prior to randomization.

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)

Outcome Description:

The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Outcome Time Frame:

Median follow-up 65 months

Safety Issue:

No

Principal Investigator

Jean-Philippe AUSSEL

Investigator Role:

Study Director

Investigator Affiliation:

Sanofi

Authority:

United States: Food and Drug Administration

Study ID:

TAX_GMA_301

NCT ID:

NCT00312208

Start Date:

August 2000

Completion Date:

February 2013

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location

Sanofi-Aventis Bridgewater, New Jersey  08807